Article in Blood advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
12 authors.
Justin S TrorySchool of Physiology, Pharmacology and Neuroscience, University of Bristol, University Walk, Biomedical Sciences Building, Bristol BS8 1TD, United Kingdom.ORCID 0000-0003-3879-5649
Attila MunkacsiSchool of Physiology, Pharmacology and Neuroscience, University of Bristol, University Walk, Biomedical Sciences Building, Bristol BS8 1TD, United Kingdom.ORCID 0000-0001-8642-8232
Kamila M ŚledźSchool of Physiology, Pharmacology and Neuroscience, University of Bristol, University Walk, Biomedical Sciences Building, Bristol BS8 1TD, United Kingdom.ORCID 0000-0001-5480-3106
Jordan VautrinotSchool of Physiology, Pharmacology and Neuroscience, University of Bristol, University Walk, Biomedical Sciences Building, Bristol BS8 1TD, United Kingdom.ORCID 0000-0001-7957-360X
Lucy J GoudswaardSchool of Physiology, Pharmacology and Neuroscience, University of Bristol, University Walk, Biomedical Sciences Building, Bristol BS8 1TD, United Kingdom.ORCID 0000-0003-1481-6871
Molly L JacksonSchool of Physiology, Pharmacology and Neuroscience, University of Bristol, University Walk, Biomedical Sciences Building, Bristol BS8 1TD, United Kingdom.ORCID 0000-0001-5990-5769
Kate J HeesomFaculty of Life Sciences, Proteomics Facility, University of Bristol, University Walk, Biomedical Sciences Building, Bristol, United Kingdom.ORCID 0000-0002-5418-5392
Samantha F MooreSchool of Physiology, Pharmacology and Neuroscience, University of Bristol, University Walk, Biomedical Sciences Building, Bristol BS8 1TD, United Kingdom.ORCID 0000-0003-0944-7055
Alastair W PooleSchool of Physiology, Pharmacology and Neuroscience, University of Bristol, University Walk, Biomedical Sciences Building, Bristol BS8 1TD, United Kingdom.ORCID 0000-0002-0868-297X
Behnam NabetHuman Biology Division, Fred Hutchinson Cancer Center, Seattle, WA.ORCID 0000-0002-6738-4200
Varinder K AggarwalSchool of Chemistry, University of Bristol, Cantock's Close, Bristol, United Kingdom.ORCID 0000-0003-0344-6430
Ingeborg HersSchool of Physiology, Pharmacology and Neuroscience, University of Bristol, University Walk, Biomedical Sciences Building, Bristol BS8 1TD, United Kingdom.ORCID 0000-0002-6467-5715
Funding
British Heart Foundation PG/16/21/32083British Heart Foundation PG/16/3/31833British Heart Foundation RG/15/16/31758British Heart Foundation SP/F/21/150023National Centre for the Replacement, Refinement and Reduction of Animals in Research NC/V001957/1
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Chemical degradation of BTK/TEC as a novel approach to inhibit platelet function. · full record | OpenQuestion